Ondine Biomedical (LON:OBI) Trading Down 7.9% – Time to Sell?

Ondine Biomedical Inc. (LON:OBI) shares dropped 7.9% on Tuesday . The company traded as low as C$12.00 and last traded at C$12.25. Approximately 53,936 shares traded hands during mid-day trading, a decline of 87% from the average daily volume of 429,282 shares. The stock had previously closed at C$13.30.

Ondine Biomedical Stock Performance

The firm has a market cap of C$3.40 billion, a P/E ratio of -408.33 and a beta of 0.10. The company has a current ratio of 0.80, a quick ratio of 8.26 and a debt-to-equity ratio of 1,847.37. The company’s 50-day moving average is C$9.90 and its two-hundred day moving average is C$8.22.

Insider Activity

In related news, insider Carolyn Cross purchased 149,225 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was acquired at an average cost of C$13.00 per share, with a total value of C$1,939,925.00. Corporate insiders own 36.69% of the company’s stock.

Ondine Biomedical Company Profile

Ondine Biomedical is a life sciences company leading the charge in breakthrough photodisinfection-based therapies to prevent and treat serious infections, including those caused by existing, emerging, and antimicrobial-resistant pathogens.

Our vision is a world free from infections. We have created a patented, platform technology (photodisinfection) to provide simple solutions to complex infections across different therapeutic areas in healthcare and industry settings.